Saroglitazar · Lipaglyn

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 diabetes mellitus, add-on to metformin (IN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:Type 2 DiabetesHypertriglyceridemia

Also approved (2)
IN
  • Type 2 diabetes mellitus, add-on to metformin
  • Hypertriglyceridemia and diabetic dyslipidemia
Product first approved 2013zyduslife.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Primary Biliary Cholangitis
NCT07216235 · Zydus Therapeutics Inc.
2026-03-24 – 2032-11 · Primary Biliary Cholangitis
What this study did
NCT07424677 · Zydus Therapeutics Inc.
2026-08-11 – 2028-11 · Primary Biliary Cholangitis
What this study did
NCT06427395 · Zydus Therapeutics Inc.
2024-07-16 – 2027-07-18 · Primary Biliary Cholangitis
What this study did
Other / comorbidity
NCT02265276 · Command Hospital, India
2014-10 – 2015-09 · Fatty Liver
What this study did
Phase 2/3 (1)
Primary Biliary Cholangitis
Phase 2 (8)
Primary Biliary Cholangitis
NCT03112681 · Zydus Therapeutics Inc.
2017-08-18 – 2020-08-07 · Primary Biliary Cirrhosis
What this study did
Other / comorbidity
NCT05011305 · Zydus Therapeutics Inc.
2021-08-18 – 2025-09-12 · Nonalcoholic Steatohepatitis, Fibrosis
What this study did
NCT03617263 · Zydus Therapeutics Inc.
2019-02-12 – 2024-10-28 · Non-alcoholic Fatty Liver Disease in Women With PCOS
What this study did
NCT03097107 · Zydus Therapeutics Inc.
2017-04-06 – 2024-01 · Dyslipidemias
What this study did
NCT05211284 · Zydus Therapeutics Inc.
2022-12-08 – 2023-10-02 · Nonalcoholic Fatty Liver Disease
What this study did
NCT03639623 · Zydus Therapeutics Inc.
2019-02-25 – 2021-12-13 · Liver Transplant; Complications, NAFLD
What this study did
NCT03863574 · Zydus Therapeutics Inc.
2019-06-12 – 2020-03-20 · Non Alcoholic Steatohepatitis
What this study did
NCT03061721 · Zydus Therapeutics Inc.
2017-04-06 – 2019-08-22 · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
What this study did
Phase 1 (6)
Other / comorbidity
NCT05045482 · Zydus Therapeutics Inc.
2021-10-21 – 2026-12-31 · Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
What this study did
NCT06825559 · Zydus Therapeutics Inc.
2025-08-05 – 2026-12-31 · Cholestatic Liver Disease
What this study did
NCT04446507 · Zydus Therapeutics Inc.
2020-07-27 – 2024-05-28 · Renal Impairment
What this study did
NCT04469920 · Zydus Therapeutics Inc.
2020-07-16 – 2022-03-21 · Hepatic Impairment
What this study did
NCT04045769 · Zydus Therapeutics Inc.
2019-08-19 – 2019-12-02 · Healthy
What this study did
NCT04112446 · Zydus Therapeutics Inc.
2019-09-20 – 2019-10-29 · Healthy
What this study did
Phase 4 (1)
Type 2 Diabetes
NCT05872269 · Zydus Lifesciences Limited
2023-07-20 – 2025-06-10 · NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias, Metabolic Syndrome
What this study did

Competitive landscape

This drug's own stage for Hypertriglyceridemia: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Saroglitazar (Lipaglyn): this drugStage not on recordSmall moleculePPAR-alpha/PPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Omega-3-Acid Ethyl Esters A (Omtryg)
ApprovedUS marketing discontinued
Small moleculeTriglyceride synthesis / VLDLnot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Olezarsen (Tryngolza)Phase 3RNA / oligonucleotideAPOC3Reliable signal
NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001)
NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001).
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaReliable signal
NCT04998981: n=344 randomized (of 353 enrolled per CT.gov). % change in fasting TG from baseline at Week 12: -34.1% (pemafibrate 0.2mg/d), -44.0% (pemafibrate 0.4mg/d), -30.5% (fenofibrate 200mg/d), +6.5% (placebo); 0.4mg/d vs placebo p<0.0001, vs fenofibrate p=0.0083.
Plozasiran (Redemplo)Phase 3RNA / oligonucleotideAPOC3Partial signal
NCT06347003: Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22).
Pravafenix
Phase 3(overall)
Small moleculeHMG-CoA reductase / PPAR-alphanot yet gradedNo reviewed efficacy summary in this indication
BW-00112Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
HRS-7249Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ION775Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
MAR001Phase 2Monoclonal antibodyANGPTL4Weak signalFeatured results are safety only in this race
RBD5044Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
SYH2070
Phase 2(overall)
RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
TipelukastPhase 2Small moleculeCysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenaseWeak signal
NCT02681055: Primary 1, cholesterol efflux capacity change from baseline to week 12: mean -0.013 (SD 0.1022) percentage of cholesterol. Primary 2, serum triglyceride change from baseline to week 8: mean -21.67 (SD 27.89) mg/dL. Single arm (n=19), no comparator; CT.gov posted results.
TLC-2716Phase 2Small moleculeLiver X receptor (LXR)not yet gradedNo reviewed efficacy summary in this indication
JMT202Phase 1/2Monoclonal antibodyβ-Klotho (KLB)not yet gradedNo reviewed efficacy summary in this indication
RN0361Phase 1/2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ALN-APOC3
Phase 1(overall)
RNA / oligonucleotideApolipoprotein C-III (APOC3)not yet gradedNo reviewed efficacy summary in this indication
ISH0688Phase 1Protein / enzyme therapeuticFGF21 receptornot yet gradedNo reviewed efficacy summary in this indication
Kylo-12Phase 1RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
VERVE-201Phase 1Gene therapy / editingANGPTL3 gene (hepatocyte genomic DNA)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lipaglyn (Saroglitazar) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Hepatic Impairment, Cirrhosis, Cholestatic Liver DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT05045482 · CT.gov ↗
What to watch
Phase 1Cholestatic Liver DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06825559 · CT.gov ↗
What to watch
2027 (1)
April 2027 (1)
Phase 3Primary Biliary CholangitisActive not recruiting
Est. primary completion 2027-04-18 · NCT06427395 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 3Primary Biliary CholangitisRecruiting
Est. primary completion 2028-07 · NCT07424677 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 3Primary Biliary CholangitisRecruiting
Est. primary completion 2032-11 · NCT07216235 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 November 2026FDA action datePDUFA target action date for saroglitazar in PBC
US, FDA · Zydus Therapeutics (wholly owned subsidiary of Zydus Lifesciences Ltd.) · Source ↗

Recent

28 May 2026Priority reviewFDA accepts the saroglitazar NDA in PBC with Priority Review
US, FDA · Zydus Therapeutics (wholly owned subsidiary of Zydus Lifesciences Ltd.) · Source ↗
29 August 2025Topline resultEPICS-III (NCT05133336) Phase 2(b)/3 met its primary endpoint
Zydus Therapeutics (wholly owned subsidiary of Zydus Lifesciences Ltd.) · Source ↗